Nanoparticle delivery of CDDO-Me remodels the tumor microenvironment and enhances vaccine therapy for melanoma

Biomaterials

Volumn 68, Issue , 2015, Pages 54-66

  Zhao, Yan ^a,b   Huo, Meirong ^a,c   Xu, Zhenghong ^a   Wang, Yuhua ^a   Huang, Leaf ^a  

^a UNC Hamner Institute for Drug Safety Sciences   (United States)

^b CHINA MEDICAL UNIVERSITY   (China)

^c CHINA PHARMACEUTICAL UNIVERSITY   (China)

Author keywords

CDDO Me; Melanoma; Nanoparticle; Peptide vaccine; Tumor microenvironment

Indexed keywords

CELL CULTURE; CELL SIGNALING; CELLS; CHEMOTHERAPY; CYTOLOGY; DERMATOLOGY; ENZYME ACTIVITY; IMMUNE SYSTEM; LYMPHOCYTES; NANOPARTICLES; ONCOLOGY; PEPTIDES; PIGMENTS; T-CELLS; TUMORS;

CALCIUM PHOSPHATE NANOPARTICLES; CDDO-ME; COMBINATION THERAPY; CYTOTOXIC T LYMPHOCYTES; MELANOMA; PEPTIDE VACCINES; POLY LACTIC GLYCOLIC ACIDS; TUMOR MICROENVIRONMENT;

VACCINES;

BARDOXOLONE METHYL; CANCER VACCINE; COLLAGEN; DOPACHROME TAUTOMERASE; NANOCARRIER; POLYGLACTIN; ANTINEOPLASTIC AGENT; MEMBRANE PROTEIN; METHYL 2-CYANO-3,12-DIOXOOLEAN-1,9-DIEN-28-OATE; NANOCAPSULE; OLEANOLIC ACID; PEPTIDE FRAGMENT; PEPTIDE SVYDFFVWL;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CHEMOTHERAPY; CANCER IMMUNIZATION; CANCER INHIBITION; CELL KILLING; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; DRUG ANTIGENICITY; DRUG BIOAVAILABILITY; DRUG DISTRIBUTION; FEMALE; FIBROBLAST; HUMAN; HUMAN CELL; LIGHT SCATTERING; LYMPHOCYTIC INFILTRATION; MELANOMA; MELANOMA CELL LINE; MOUSE; NANOENCAPSULATION; NONHUMAN; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; SIGNAL TRANSDUCTION; SURFACE CHARGE; TRANSMISSION ELECTRON MICROSCOPY; TUMOR ASSOCIATED FIBROBLAST; TUMOR ASSOCIATED LEUKOCYTE; TUMOR MICROENVIRONMENT; TUNEL ASSAY; ANALOGS AND DERIVATIVES; ANIMAL; APOPTOSIS; C57BL MOUSE; CHEMISTRY; DRUG EFFECTS; DRUG POTENTIATION; PARTICLE SIZE; PATHOLOGY; TREATMENT OUTCOME; TUMOR CELL LINE; ULTRASTRUCTURE;

ANIMALIA;

ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; CANCER VACCINES; CELL LINE, TUMOR; DRUG SYNERGISM; FEMALE; MELANOMA; MEMBRANE PROTEINS; MICE; MICE, INBRED C57BL; NANOCAPSULES; OLEANOLIC ACID; PARTICLE SIZE; PEPTIDE FRAGMENTS; TREATMENT OUTCOME; TUMOR MICROENVIRONMENT;

EID: 84939606768     PISSN: 01429612     EISSN: 18785905     Source Type: Journal    
DOI: 10.1016/j.biomaterials.2015.07.053     Document Type: Article

References (53)

1. Denies S., Cicchelero L., Van Audenhove I., Sanders N.N. Combination of interleukin-12 gene therapy, metronomic cyclophosphamide and DNA cancer vaccination directs all arms of the immune system towards tumor eradication. J. Control. Release 2014, 187:175-182.
2. Tan Z., Zhou J., Cheung A.K., Yu Z., Cheung K.W., Liang J., et al. Vaccine-elicited CD8+ T cells cure mesothelioma by overcoming tumor-induced immunosuppressive environment. Cancer Res. 2014, 74:6010-6021.
3. Venanzi F., Shifrin V., Sherman M., Gabai V., Kiselev O., Komissarov A., et al. Broad-spectrum anti-tumor and anti-metastatic DNA vaccine based on p62-encoding vector. Oncotarget 2013, 4:1829-1835.
4. Schwartzentruber D.J., Lawson D.H., Richards J.M., Conry R.M., Miller D.M., Treisman J., et al. gp100 peptide vaccine and interleukin-2 in patients with advanced melanoma. N. Engl. J. Med. 2011, 364:2119-2127.
5. Slingluff C.L., Petroni G.R., Chianese-Bullock K.A., Smolkin M.E., Ross M.I., Haas N.B., et al. Randomized multicenter trial of the effects of melanoma-associated helper peptides and cyclophosphamide on the immunogenicity of a multipeptide melanoma vaccine. J. Clin. Oncol. 2011, 29:2924-2932.
6. Weber J.S., Kudchadkar R.R., Yu B., Gallenstein D., Horak C.E., Inzunza H.D., et al. Safety, efficacy, and biomarkers of nivolumab with vaccine in ipilimumab-refractory or -naive melanoma. J. Clin. Oncol. 2013, 31:4311-4318.
7. Mellman I., Coukos G., Dranoff G. Cancer immunotherapy comes of age. Nature 2011, 480:480-489.
8. Sharma P., Wagner K., Wolchok J.D., Allison J.P. Novel cancer immunotherapy agents with survival benefit: recent successes and next steps. Nat. Rev. Cancer 2011, 11:805-812.
9. Buhrman J.D., Slansky J.E. Improving T cell responses to modified peptides in tumor vaccines. Immunol. Res. 2013, 55:34-47.
10. Devaud C., John L.B., Westwood J.A., Darcy P.K., Kershaw M.H. Immune modulation of the tumor microenvironment for enhancing cancer immunotherapy. Oncoimmunology 2013, 2:e25961.
11. Xu Z., Ramishetti S., Tseng Y.C., Guo S., Wang Y., Huang L. Multifunctional nanoparticles co-delivering Trp2 peptide and CpG adjuvant induce potent cytotoxic T-lymphocyte response against melanoma and its lung metastasis. J. Control. Release Off. J. Control. Release Soc. 2013, 172:259-265.
12. Xu Z., Wang Y., Zhang L., Huang L. Nanoparticle-delivered transforming growth factor-beta siRNA enhances vaccination against advanced melanoma by modifying tumor microenvironment. ACS Nano 2014, 8:3636-3645.
13. Chen C.A., Ho C.M., Chang M.C., Sun W.Z., Chen Y.L., Chiang Y.C., et al. Metronomic chemotherapy enhances antitumor effects of cancer vaccine by depleting regulatory T lymphocytes and inhibiting tumor angiogenesis. Mol. Ther. J. Am. Soc. Gene Ther. 2010, 18:1233-1243.
14. Emens L.A., Asquith J.M., Leatherman J.M., Kobrin B.J., Petrik S., Laiko M., et al. Timed sequential treatment with cyclophosphamide, doxorubicin, and an allogeneic granulocyte-macrophage colony-stimulating factor-secreting breast tumor vaccine: a chemotherapy dose-ranging factorial study of safety and immune activation. J. Clin. Oncol. 2009, 27:5911-5918.
15. Gameiro S.R., Caballero J.A., Higgins J.P., Apelian D., Hodge J.W. Exploitation of differential homeostatic proliferation of T-cell subsets following chemotherapy to enhance the efficacy of vaccine-mediated antitumor responses. Cancer Immunol. Immunother. 2011, 60:1227-1242.
16. Neninger E., Verdecia B.G., Crombet T., Viada C., Pereda S., Leonard I., et al. Combining an EGF-based cancer vaccine with chemotherapy in advanced nonsmall cell lung cancer. J. Immunother. 2009, 32:92-99.
17. Liby K.T., Sporn M.B. Synthetic oleanane triterpenoids: multifunctional drugs with a broad range of applications for prevention and treatment of chronic disease. Pharmacol. Rev. 2012, 64:972-1003.
18. Wang Y.Y., Zhe H., Zhao R. Preclinical evidences toward the use of triterpenoid CDDO-Me for solid cancer prevention and treatment. Mol. Cancer 2014, 13:30.
19. Deeb D., Gao X., Jiang H., Dulchavsky S.A., Gautam S.C. Oleanane triterpenoid CDDO-Me inhibits growth and induces apoptosis in prostate cancer cells by independently targeting pro-survival Akt and mTOR. Prostate 2009, 69:851-860.
20. Liu Y.B., Gao X.H., Deeb D., Gautam S.C. Oleanane triterpenoid CDDO-Me inhibits Akt activity without affecting PDK1 kinase or PP2A phosphatase activity in cancer cells. Biochem. Biophys. Res. Commun. 2012, 417:570-575.
21. Qin Y., Deng W., Ekmekcioglu S., Grimm E.A. Identification of unique sensitizing targets for anti-inflammatory CDDO-Me in metastatic melanoma by a large-scale synthetic lethal RNAi screening. Pigment. Cell Melanoma Res. 2013, 26:97-112.
22. Ryu K., Susa M., Choy E., Yang C., Hornicek F.J., Mankin H.J., et al. Oleanane triterpenoid CDDO-Me induces apoptosis in multidrug resistant osteosarcoma cells through inhibition of Stat3 pathway. BMC Cancer 2010, 10.
23. Deeb D., Gao X., Arbab A.S., Barton K., Dulchavsky S.A., Gautam S.C. CDDO-Me: a novel synthetic triterpenoid for the treatment of pancreatic cancer. Cancers 2010, 2:1779-1793.
24. Gao X., Liu Y., Deeb D., Liu P., Liu A., Arbab A.S., et al. ROS mediate proapoptotic and antisurvival activity of oleanane triterpenoid CDDO-Me in ovarian cancer cells. Anticancer Res. 2013, 33:215-221.
25. Shishodia S., Sethi G., Konopleva M., Andreeff M., Aggarwal B.B. A synthetic triterpenoid, CDDO-Me, inhibits I kappa B alpha, kinase and enhances apoptosis induced by TNF and chemotherapeutic agents through down-regulation of expression of nuclear factor kappa B-regulated gene products in human leukemic cells. Clin. Cancer Res. 2006, 12:1828-1838.
26. Nagaraj S., Youn J.I., Weber H., Iclozan C., Lu L., Cotter M.J., et al. Anti-inflammatory triterpenoid blocks immune suppressive function of MDSCs and improves immune response in cancer. Clin. Cancer Res. Off. J. Am. Assoc. Cancer Res. 2010, 16:1812-1823.
27. Liao D., Liu Z., Wrasidlo W.J., Luo Y., Nguyen G., Chen T., et al. Targeted therapeutic remodeling of the tumor microenvironment improves an HER-2 DNA vaccine and prevents recurrence in a murine breast cancer model. Cancer Res. 2011, 71:5688-5696.
28. Hu Y., Haynes M.T., Wang Y., Liu F., Huang L. A highly efficient synthetic vector: nonhydrodynamic delivery of DNA to hepatocyte nuclei in vivo. ACS Nano 2013, 7:5376-5384.
29. Li J., Yang Y., Huang L. Calcium phosphate nanoparticles with an asymmetric lipid bilayer coating for siRNA delivery to the tumor. J. Control. Release Off. J. Control. Release Soc. 2012, 158:108-114.
30. Zhang Y., Peng L., Mumper R.J., Huang L. Combinational delivery of c-myc siRNA and nucleoside analogs in a single, synthetic nanocarrier for targeted cancer therapy. Biomaterials 2013, 34:8459-8468.
31. Zhang Y., Schwerbrock N.M., Rogers A.B., Kim W.Y., Huang L. Codelivery of VEGF siRNA and gemcitabine monophosphate in a single nanoparticle formulation for effective treatment of NSCLC. Mol. Ther. J. Am. Soc. Gene Ther. 2013, 21:1559-1569.
32. Ishida E., Managit C., Kawakami S., Nishikawa M., Yamashita F., Hashida M. Biodistribution characteristics of galactosylated emulsions and incorporated probucol for hepatocyte-selective targeting of lipophilic drugs in mice. Pharm. Res. 2004, 21:932-939.
33. Obermajer N., Wong J.L., Edwards R.P., Odunsi K., Moysich K., Kalinski P. PGE(2)-driven induction and maintenance of cancer-associated myeloid-derived suppressor cells. Immunol. Investig. 2012, 41:635-657.
34. Shirota Y., Shirota H., Klinman D.M. Intratumoral injection of CpG oligonucleotides induces the differentiation and reduces the immunosuppressive activity of myeloid-derived suppressor cells. J. Immunol. 2012, 188:1592-1599.
35. Sinha P., Clements V.K., Ostrand-Rosenberg S. Interleukin-13-regulated M2 macrophages in combination with myeloid suppressor cells block immune surveillance against metastasis. Cancer Res. 2005, 65:11743-11751.
36. Wu A., Wei J., Kong L.Y., Wang Y., Priebe W., Qiao W., et al. Glioma cancer stem cells induce immunosuppressive macrophages/microglia. Neuro Oncol. 2010, 12:1113-1125.
37. Kashimura S., Saze Z., Terashima M., Soeta N., Ohtani S., Osuka F., et al. CD83(+) dendritic cells and Foxp3(+) regulatory T cells in primary lesions and regional lymph nodes are inversely correlated with prognosis of gastric cancer. Gastric Cancer Off. J. Int. Gastric Cancer Assoc. Jpn. Gastric Cancer Assoc. 2012, 15:144-153.
38. Kim S., Lee A., Lim W., Park S., Cho M.S., Koo H., et al. Zonal difference and prognostic significance of foxp3 regulatory T cell infiltration in breast cancer. J. Breast Cancer 2014, 17:8-17.
39. Mattarollo S.R., Steegh K., Li M., Duret H., Foong Ngiow S., Smyth M.J. Transient Foxp3(+) regulatory T-cell depletion enhances therapeutic anticancer vaccination targeting the immune-stimulatory properties of NKT cells. Immunol. Cell Biol. 2013, 91:105-114.
40. Diaz-Montero C.M., Finke J., Montero A.J. Myeloid-derived suppressor cells in cancer: therapeutic, predictive, and prognostic implications. Seminars Oncol. 2014, 41:174-184.
41. Weed D.T., Vella J.L., Reis I.M., De la Fuente A.C., Gomez C., Sargi Z., et al. Tadalafil reduces myeloid-derived suppressor cells and regulatory T cells and promotes tumor immunity in patients with head and neck squamous cell carcinoma. Clin. Cancer Res. Off. J. Am. Assoc. Cancer Res. 2015, 21:39-48.
42. Wallecha A., Singh R., Malinina I. Listeria monocytogenes (Lm)-LLO immunotherapies reduce the immunosuppressive activity of myeloid-derived suppressor cells and regulatory T cells in the tumor microenvironment. J. Immunother. 2013, 36:468-476.
43. Alizadeh D., Larmonier N. Chemotherapeutic targeting of cancer-induced immunosuppressive cells. Cancer Res. 2014, 74:2663-2668.
44. Ostrand-Rosenberg S., Sinha P., Beury D.W., Clements V.K. Cross-talk between myeloid-derived suppressor cells (MDSC), macrophages, and dendritic cells enhances tumor-induced immune suppression. Seminars Cancer Biol. 2012, 22:275-281.
45. Whiteside T.L. The tumor microenvironment and its role in promoting tumor growth. Oncogene 2008, 27:5904-5912.
46. Kuriyan A.E., Lehmann G.M., Kulkarni A.A., Woeller C.F., Feldon S.E., Hindman H.B., et al. Electrophilic PPARgamma ligands inhibit corneal fibroblast to myofibroblast differentiation in vitro: a potentially novel therapy for corneal scarring. Exp. Eye Res. 2012, 94:136-145.
47. Guo S.T., Lin C.M., Xu Z.H., Miao L., Wang Y.H., Huang L. Co-delivery of cisplatin and rapamycin for enhanced anticancer therapy through synergistic effects and microenvironment modulation. ACS Nano 2014, 8:4996-5009.
48. Zhang J., Miao L., Guo S., Zhang Y., Zhang L., Satterlee A., et al. Synergistic anti-tumor effects of combined gemcitabine and cisplatin nanoparticles in a stroma-rich bladder carcinoma model. J. Control. Release Off. J. Control. Release Soc. 2014, 182:90-96.
49. Johansson A., Ganss R. Remodeling of tumor stroma and response to therapy. Cancers 2012, 4:340-353.
50. Matejuk A., Collet G., Nadim M., Grillon C., Kieda C. MicroRNAs and tumor vasculature normalization: impact on anti-tumor immune response. Archivum Immunol. Ther. Exp. 2013, 61:285-299.
51. Konkankit V.V., Kim W., Koya R.C., Eskin A., Dam M.A., Nelson S., et al. Decitabine immunosensitizes human gliomas to NY-ESO-1 specific T lymphocyte targeting through the Fas/Fas ligand pathway. J. Transl. Med. 2011, 9:192.
52. Solary E., Micheau O., Dimanche-Boitrel M.T., Martin F. The Fas/Fas-ligand system: implications in the antitumor immune response and in the activity of cytotoxic agents. Bull. Cancer 1998, 85:685-694.
53. Viard-Leveugle I., Gaide O., Jankovic D., Feldmeyer L., Kerl K., Pickard C., et al. TNF-alpha and IFN-gamma are potential inducers of Fas-mediated keratinocyte apoptosis through activation of inducible nitric oxide synthase in toxic epidermal necrolysis. J. Invest. Dermatol. 2013, 133:489-498.